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Abstract
We previously reported a case in which steroid-induced psychosis was eliminated with risperidone treatment in a
patient with polyarteritis nodosa (PN). In the present report, we longitudinally tracked the serum levels of brain-
derived neurotrophic factor (BDNF). We found that corticosteroid lowered serum BDNF levels, and improvement of
psychiatric symptoms was intact with the serum BDNF levels seen in the patients.
Introduction
There are several reports demonstrating the effective-
ness of risperidone in treating steroid psychosis [1,2].
We have also previously demonstrated that risperidone
did not change serum brain-derived neurotrophic factor
(BDNF) levels in patients with schizophrenia [3]. BDNF
is associated with psychiatric diseases such as depression
or schizophrenia [1]. In the present case, risperidone
rapidly diminished our patient’s psychiatric symptoms
without severe adverse effects. Corticosteroids suppress
BDNF levels in the brain, which leads to atrophy of the
hippocampus [4]. To the best of our knowledge, this is
the first report showing longitudinal tracking of serum
BDNF levels in a case of steroid psychosis in a patient
with polyarteritis nodosa (PN).
Case presentation
Our patient, a 69-year-old woman, had had a diagnosis
of PN for 4 years with no previous psychiatric history.
Her major symptoms of PN were hypertension, pleuritis,
vasculitis, a raised platelet count, and a high level of C-
reactive protein. She did not have positive findings for
vasculitis in the brain on MRI or magnetic resonance
angiography (MRA). She had been treated with steroid
pulse therapy (intravenous administration of methyl-
prednisolone at 45 mg/day) followed by betamethasone
at 4 mg/day. After 1 month at this dosage, she had
experienced a mixed state that included being more
talkative than usual, feeling hyperactive, and excited,
crying, feeling depressed, and having rapid mood swings,
persecutory delusions, and auditory hallucinations. Her
score on the Brief Psychiatric Rating Scale (BPRS) was
33 points. Risperidone was started at 1 mg/day and
increased to 2 mg/day, and the dose of betamethasone
was continued at the same dose (4 mg/day). Her psy-
chiatric symptoms gradually improved, and she reached
remission 3 weeks after the initiation of risperidone
treatment. Since she demonstrated mild finger tremor,
her dose of risperidone was decreased to 1 mg/day with-
out worsening of her psychiatric symptoms. During her
course of psychiatric symptoms, we longitudinally mea-
sured her serum BDNF levels, as shown in Figure 1.
Conclusions
Corticosteroid reduced serum BDNF levels and kept
those levels lower, and risperidone did not cause the
serum BDNF levels to recover. In addition, risperidone
is effective for use in steroid psychosis patients with PN,
and improvement of psychotic symptoms in the patient
was independent of serum BDNF levels.
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Figure 1 Changes in serum brain-derived neurotrophic factor (BDNF) levels and Brief Psychiatric Rating Scale (BPRS) scores.
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